# SLN12140 in Adult Participants With IgA Nephropathy in China

> **NCT07553494** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Linno Pharmaceuticals, Inc.** · enrollment: 48 (estimated)

## Conditions studied

- IgA Nephropathy (IgAN)

## Interventions

- **DRUG:** SLN12140
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT07553494
- **Lead sponsor:** Linno Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-29
- **Primary completion:** 2027-12
- **Final completion:** 2028-12
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2026-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07553494

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07553494, "SLN12140 in Adult Participants With IgA Nephropathy in China". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT07553494. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*